ArticleCell death & disease2015

Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.

H Sugimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.